Insider · CIK 0001855689
Sharon Townson
Files at GLUE (Monte Rosa Therapeutics, Inc.). First filing Jan 5, 2026, latest Jul 7, 2026.
In brief
Sharon Townson files SEC Form 4 as officer at GLUE (Monte Rosa Therapeutics, Inc.). Since Jan 5, 2026, Sharon Townson has reported 0 open-market buys worth $0 and 5 open-market sells worth $424k, the latest filed on Jul 7, 2026.
A track record needs three past buys with six months of prices behind them; Sharon Townson has 0, so none is measured yet.
The newest scored trade: sold $140k of GLUE on Jul 6, 2026, filed Jul 7, 2026, scored 6 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 5 sells worth $424k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GLUE: Monte Rosa Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 6Weak | Monte Rosa Therapeutics, Inc. | $140k 6,000 shares | -8% | +455% from low-8% from high | |
| 2Weak | Monte Rosa Therapeutics, Inc. | $60k 3,000 shares | -4% | +394% from low-18% from high | |
| 2Weak | Monte Rosa Therapeutics, Inc. | $57k 3,000 shares | -4% | +339% from low-27% from high | |
| 5Weak | Monte Rosa Therapeutics, Inc. | $119k 6,000 shares | -8% | +372% from low-22% from high | |
| 37Weak | Monte Rosa Therapeutics, Inc. | $48k 3,155 shares | -4% | +289% from low-23% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 29, 2026 | GLUE MONTE ROSA THERAPEUTICS INC | 24,000 0.03% of outstanding | $465k | May 29, 2026 | none |
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +6,000 | $6.14 | $37k | 73,845 | Jul 7, 2026 |
| Jul 6, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,600 | $23.25 | $130k | 68,245 | Jul 7, 2026 |
| Jul 6, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -400 | $24.13 | $9,652 | 67,845 | Jul 7, 2026 |
| Jul 6, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 197,290 | Jul 7, 2026 |
| Jun 23, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +3,000 | $6.14 | $18k | 70,845 | Jun 25, 2026 |
| Jun 23, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,000 | $20.00 | $60k | 67,845 | Jun 25, 2026 |
| Jun 23, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,000 | $0.00 | $0 | 203,290 | Jun 25, 2026 |
| Jun 17, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +3,000 | $6.14 | $18k | 70,845 | Jun 18, 2026 |
| Jun 17, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,000 | $19.00 | $57k | 67,845 | Jun 18, 2026 |
| Jun 17, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,000 | $0.00 | $0 | 206,290 | Jun 18, 2026 |
| May 29, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +6,000 | $6.14 | $37k | 73,845 | Jun 1, 2026 |
| May 29, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -6,000 | $19.87 | $119k | 67,845 | Jun 1, 2026 |
| May 29, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 209,290 | Jun 1, 2026 |
| Jan 2, 2026 | GLUE Monte Rosa Therapeutics, Inc. | AGrant or award Common Stock | +35,000 | - | - | 71,000 | Jan 5, 2026 |
| Jan 5, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock | -3,155 | $15.17 | $48k | 67,845 | Jan 5, 2026 |
| Jan 2, 2026 | GLUE Monte Rosa Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +158,000 | $0.00 | $0 | 158,000 | Jan 5, 2026 |
Questions about Sharon Townson
Answered from the filings on this page, as of the latest one.
Is Sharon Townson buying or selling?
In the last 12 months Sharon Townson reported 0 open-market buys worth $0 and 5 open-market sells worth $424k on SEC Form 4; the latest was sold $140k of GLUE on Jul 6, 2026. Grants, option exercises and tax withholding are not counted.
How did Sharon Townson's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sharon Townson has 0.
Where does Sharon Townson file Form 4?
Sharon Townson has filed Form 4 at GLUE (Monte Rosa Therapeutics, Inc.) as Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.